We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598160

CAS#: 1431-30-7

Description: L589-420 is an inhibitor of sodium pump in human erythrocytes.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-04-07. Prices are subject to change without notice.

L589-420 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 598160
Name: L589-420
CAS#: 1431-30-7
Chemical Formula: C14H14Cl2O4
Exact Mass: 316.0269
Molecular Weight: 317.16
Elemental Analysis: C, 53.02; H, 4.45; Cl, 22.35; O, 20.18

Synonym: L589-420; L 589-420; L-589-420; L589 420; L 589 420; L-589 420;

IUPAC/Chemical Name: (E)-2-(2,3-dichloro-4-(2-ethylbut-2-enoyl)phenoxy)acetic acid


InChi Code: InChI=1S/C14H14Cl2O4/c1-3-8(4-2)14(19)9-5-6-10(13(16)12(9)15)20-7-11(17)18/h3,5-6H,4,7H2,1-2H3,(H,17,18)/b8-3+

SMILES Code: O=C(O)COC1=CC=C(C(/C(CC)=C/C)=O)C(Cl)=C1Cl

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis. 2017 May 1;64(9):1154-1162. doi: 10.1093/cid/cix126. PubMed PMID: 28199495; PubMed Central PMCID: PMC5399935.